May Mo

1.8k total citations · 1 hit paper
21 papers, 1.3k citations indexed

About

May Mo is a scholar working on Oncology, Physiology and Dermatology. According to data from OpenAlex, May Mo has authored 21 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Physiology and 5 papers in Dermatology. Recurrent topics in May Mo's work include Neutropenia and Cancer Infections (6 papers), Asthma and respiratory diseases (6 papers) and Allergic Rhinitis and Sensitization (4 papers). May Mo is often cited by papers focused on Neutropenia and Cancer Infections (6 papers), Asthma and respiratory diseases (6 papers) and Allergic Rhinitis and Sensitization (4 papers). May Mo collaborates with scholars based in United States, Canada and Spain. May Mo's co-authors include Jane R. Parnes, René van der Merwe, Janet M. Griffiths, Stephanie L. Roseti, Jonathan Corren, Eric L. Simpson, Dewei She, William A. Rees, Gene Colice and Primal Kaur and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

May Mo

20 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tezepelumab in Adults with Uncontrolled Asthma

2017 677 citations Jonathan Corren, Jane R. Parnes et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
May Mo United States	9	842	508	414	374	370	21	1.3k
Julie Olsson United States	11	589 0.7×	597 1.2×	212 0.5×	286 0.8×	97 0.3×	15	1.1k
J. Thirlwell United Kingdom	12	1.7k 2.1×	1.3k 2.5×	1.0k 2.5×	243 0.6×	79 0.2×	17	1.9k
Lynn E. Katz United States	3	1.6k 1.9×	1.2k 2.3×	378 0.9×	429 1.1×	48 0.1×	8	1.8k
Martin Blogg United Kingdom	13	2.3k 2.7×	1.7k 3.4×	1.4k 3.3×	285 0.8×	95 0.3×	36	2.5k
Takaaki Konishi Japan	14	53 0.1×	236 0.5×	81 0.2×	105 0.3×	53 0.1×	101	853
Maija Halme Finland	20	197 0.2×	467 0.9×	32 0.1×	68 0.2×	20 0.1×	52	920
Katerina Samara Greece	15	348 0.4×	805 1.6×	50 0.1×	102 0.3×	8 0.0×	35	1.0k
Katie Bechman United Kingdom	16	87 0.1×	126 0.2×	24 0.1×	185 0.5×	79 0.2×	58	993
Chien‐Ying Liu Taiwan	20	98 0.1×	434 0.9×	19 0.0×	92 0.2×	10 0.0×	76	1.2k
Alessandro Tomelleri Italy	21	199 0.2×	547 1.1×	15 0.0×	185 0.5×	43 0.1×	84	1.4k

Countries citing papers authored by May Mo

Since Specialization

Citations

This map shows the geographic impact of May Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by May Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites May Mo more than expected).

Fields of papers citing papers by May Mo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by May Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by May Mo. The network helps show where May Mo may publish in the future.

Co-authorship network of co-authors of May Mo

This figure shows the co-authorship network connecting the top 25 collaborators of May Mo. A scholar is included among the top collaborators of May Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with May Mo. May Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jiang, Xun, et al.. (2024). LEAP: the latent exchangeability prior for borrowing information from historical data. Biometrics. 80(3). 1 indexed citations

Merrill, Joan T., et al.. (2023). Improving resource utilisation in SLE drug development through innovative trial design. Lupus Science & Medicine. 10(2). e000890–e000890. 2 indexed citations

Jiang, Xun, et al.. (2023). A Bayesian Adaptive Umbrella Trial Design with Robust Information Borrowing for Screening Multiple Combination Therapies. Statistics in Biopharmaceutical Research. 16(2). 171–181. 1 indexed citations

Gwon, Yeongjin, May Mo, Ming‐Hui Chen, et al.. (2020). Network meta‐regression for ordinal outcomes: Applications in comparing Crohn's disease treatments. Statistics in Medicine. 39(13). 1846–1870. 4 indexed citations

Warady, Bradley A., et al.. (2020). Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis. Pediatric Nephrology. 35(9). 1679–1697. 12 indexed citations

Wechsler, Michael E., Gene Colice, Janet M. Griffiths, et al.. (2020). SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respiratory Research. 21(1). 264–264. 60 indexed citations

Menzies‐Gow, Andrew, Gene Colice, Janet M. Griffiths, et al.. (2020). NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respiratory Research. 21(1). 266–266. 70 indexed citations

Basu, Cynthia, Xiaoye Ma, May Mo, et al.. (2020). Pharmacokinetic/pharmacodynamic data extrapolation models for improved pediatric efficacy and toxicity estimation, with application to secondary hyperparathyroidism. Pharmaceutical Statistics. 19(6). 882–896. 1 indexed citations

Corren, Jonathan, Jane R. Parnes, Liangwei Wang, et al.. (2018). Tezepelumab demonstrates clinically meaningful improvements in asthma control (ACQ-6) in patients with uncontrolled asthma: results from a phase 2b clinical trial. Journal of Allergy and Clinical Immunology. 141(2). AB80–AB80. 3 indexed citations

10.

Simpson, Eric L., Jane R. Parnes, Dewei She, et al.. (2018). Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. Journal of the American Academy of Dermatology. 80(4). 1013–1021. 252 indexed citations

11.

Corren, Jonathan, Jane R. Parnes, May Mo, et al.. (2017). Tezepelumab in Adults with Uncontrolled Asthma. New England Journal of Medicine. 377(10). 936–946. 677 indexed citations breakdown →

12.

Sandborn, William J., Marcoli Cyrille, Mark Berner Hansen, et al.. (2017). Efficacy and Safety of Abrilumab (AMG 181/MEDI 7183) Therapy for Moderate to Severe Crohn’s Disease. Gastroenterology. 152(5). S598–S598. 8 indexed citations

13.

Balducci, Lodovico, May Mo, Esteban Abella, & Alan Saven. (2014). Retrospective Analysis of Relative Dose Intensity in Patients With Non-Hodgkin Lymphoma Receiving CHOP-based Chemotherapy and Pegfilgrastim. American Journal of Clinical Oncology. 37(6). 603–610. 11 indexed citations

14.

Abella, Steve, Alvydas Česas, Adina Croitoru, et al.. (2013). Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology. 31(4_suppl). LBA445–LBA445. 4 indexed citations

15.

Pintér, Tamás, Esteban Abella, Alvydas Česas, et al.. (2013). Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology. 31(15_suppl). 3575–3575. 4 indexed citations

16.

Le, Quynh‐Thu, Harold E. Kim, Charles Schneider, et al.. (2011). Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study. Journal of Clinical Oncology. 29(20). 2808–2814. 142 indexed citations

17.

Hecht, J. Randolph, Madhavan V. Pillai, Russell Gollard, et al.. (2010). A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy. Clinical Colorectal Cancer. 9(2). 95–101. 50 indexed citations

18.

Gregory, Stephanie A., Lee S. Schwartzberg, May Mo, Jorge Sierra, & Charles Vogel. (2010). Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegf lgrastim clinical trials: a retrospective analysis. Community Oncology. 7(7). 297–308. 26 indexed citations

19.

Gregory, Stephanie A., May Mo, Charles L. Vogel, Jorge Sierra, & Lee S. Schwartzberg. (2009). Reported Bone Pain in Cancer Patients Receiving Chemotherapy in Pegfilgrastim Clinical Trials: A Retrospective Analysis.. Blood. 114(22). 4561–4561. 6 indexed citations

20.

Quinn, Frank A., et al.. (2002). A Comparison of Different Sample Matrices for Evaluating Functional Sensitivity, Imprecision and Dilution Linearity of the Abbott ARCHITECT® i2000® TSH Assay. Clinical Chemistry and Laboratory Medicine (CCLM). 40(7). 709–12. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact